Home / Resource Library / The efficacy and safety of the JAK 1/2 inhibitor ruxolitinib in TCLThe efficacy and safety of the JAK 1/2 inhibitor ruxolitinib in TCL Results of a study investigating ruxolitnib for treatment of relapsed T-cell lymphomas.